Zinbryta Lawsuit Attorney in Florida
Jeffrey D. DeCarlo stands up for patients
Zinbryta (daclizumab) is a drug first introduced in 2016 to treat adults who suffer from relapsing forms of multiple sclerosis (MS). The drug is manufactured by AbbVie, Inc. and Biogen, Inc. and is administered via injection.
In the United States, Zinbryta was only available through a Risk Evaluation and Mitigation Strategy (REMS) and recommended only as a treatment for patients who have failed to respond to other MS drugs, due to a known risk of liver injury. However, it turns out that the drug is linked to even more serious side effects.
Specifically, there have been at least 12 reported cases of encephalitis and meningoencephalitis, deadly medical conditions that cause swelling and inflammation in the brain, linked to Zinbryta. At least three of these cases proved fatal, all occurring in the United States. An investigation by the European Medicines Agency (EMA) recommended a ban for the drug in the European Union due to this risk of serious and potentially fatal brain injury. In early March 2018, a worldwide Zinbryta recall was announced.
Understanding the warning signs of Zinbryta brain injuries
Prior to the recall, Zinbryta was prescribed to approximately 8,000 patients worldwide. If you or a loved one was prescribed Zinbryta, be aware of the potential symptoms of encephalitis or meningoencephalitis, including:
- Persistent fever
- Severe headaches
- Yellowing of skin or eyes
If you have any reason to suspect these serious Zinbryta side effects, seek medical help right away. Then, contact an experienced attorney. Jeffrey D. DeCarlo, P.A. is currently reviewing cases for patients affected by this dangerous drug. Contact us today to schedule your free consultation.